Conference Day Two | Thursday, October 2

7:45 am Check-in & Coffee

Streamlining Regulatory Strategies & Advancing Cell Delivery for Successful iPSC Therapy Development

8:30 am Panel Discussion: Understanding Evolving Frameworks & Addressing Regulatory Expectations Towards iPSC Based Therapies

Synopsis

  • Exploring the challenges posed by regulatory inconsistencies between agencies and strategies to navigate evolving requirements for iPSC therapies
  • Discussing best practices to propose new data, technologies and assays to regulators

9:30 am Case Study: Discussing the Regulatory Pathway to Clinic

  • Eric Law CMC Regulatory Affairs, Century Therapeutics

Synopsis

  • Highlighting the journey of advancing gene-edited iPSC therapies from preclinical to clinical trials, sharing lessons learned and insights on meeting regulatory and CMC expectations  

10:00 am Refining the Path to Delivering Cells to Patients

  • Doris taylor Chief Executive Officer & Co-Founder, Organamet

Synopsis

  • Ensuring iPSC-derived cell delivery methods are accessible, viable, and adaptable to a range of clinical settings
  • Applying lessons from iPSC based organ development to optimize trial design and prepare for future applications

10:30 am Morning Break & Networking

Preclinical Track

Demonstrating Safety for iPSC-Derived Therapies to Ensure a Smooth Path to Clinic

11:30 am Roundtable Discussion: Analyzing Different Approaches to Toxicology Assays

Synopsis

  • Diving into different methods to conduct residual IPS assays and how to best present results to regulators
  • Comparing and contrasting toxicology assays between different cell types

Selecting the Right Conditions to Nurture Desired iPSC Differentiation

12:00 pm Accurately Recapitulating T-Cell Development for Autoimmune & Oncology Applications

  • Ran Jing Instructor, Harvard Medical School, Boston Children’s Hospital

Synopsis

  • Strategies to mimic thymic selection and T-cell maturation in vitro to ensure functional and self-tolerant T-cell populations
  • Tailoring iPSC-derived T-cell for tumor-specific or autoimmune-resistant profiles through precise developmental control
  • Overcoming current challenges in achieving lineage specificity and scalability for clinical-grade T-cell products

Process Development & CMC Track

Enabling Scalable & Reliable Manufacturing of iPSCDerived Cells for Broad Therapeutic Impact

11:30 am Session Reserved for ThermoFisher

12:00 pm Standardizing iPSC Differentiation to Improve Reproducibility in Manufacturing

  • Jason Mills Senior Director - Process Development, Century Therapeutics

Synopsis

  • Overcoming heterogeneity and variability in large-scale differentiation processes
  • Implementing robust quality control strategies to ensure batch-to-batch consistency
  • Aligning differentiation protocols with GMP requirements for clinical translation

12:30 pm Lunch

1:30 pm Evaluating the Impact of Cell Culture Environments on iPSC Differentiation

Synopsis

  • Highlighting the process of differentiating iPSCs to iMSCs
  • Discussing how factors such as temperature, timing, culture media, nutrients, and more impact the behaviour of iPSC-derived cells

2:00 pm Advanced Technologies for Engineering iPSC-Derived Tissues & Organs

Synopsis

  • Cutting-edge biotechnologies for functional tissue and organ engineering
  • Personalized biomaterials for engineering autologous iPSCderived tissues
  • 3D and 4D printing of personalized tissues and organs
  • Integration of micro/nanoelectronics into engineered tissues to create cyborg and bionic organs

Advancing Cell Characterization Techniques & Parameters for Validation of Processes

1:30 pm Defining Parameters to Assess the Quality of Desired End Cell Type

  • Lina Sui Senior Director, Process and Analytical Development, Sana Biotechnology

Synopsis

  • Implementing strategies to validate the accuracy of cell differentiation
  • Exploring morphological, molecular, and functional assays to confirm cell identity
  • How can we evaluate the genomic stability of the final cell product?

2:00 pm Finding the Right Balance when Monitoring iPSCs

Synopsis

  • How often should differentiating cells be analyzed
  • Are there any differentiation milestones that need to be observed?
  • What needs to be observed at every point (morphology, marker expression, purity)?

2:30 pm Afternoon Break

Leveraging iPSCs Beyond Cellular Therapies

3:00 pm Advancing Cancer Modeling with iPSCs: Current Approaches & Opportunities

Synopsis

  • Modeling hereditary cancers using iPSC-derived cancer organoids
  • Understanding novel signaling pathways in cancer progression
  • Uncovering novel targets for drug and future cell therapies

3:30 pm Harnessing iPSCs for Drug Development, Applications in Drug Screening & Hit Identification

Synopsis

  • Using iPSC-CM reporter lines for small molecule screening
  • Effects of identified hits on gene expression and cardiomyocyte morphology

4:00 pm Closing Remarks

4:10 pm End of the 5th iPSC Drug Development Summit